SREBP1c mRNA was elevated in MASLD patient livers (Kohjima et al., 2008) and its chronic activation contributed to MASLD progression (Kawano and Cohen, 2013) SREBP1 has become a target for MASLD treatment (Ju et al., 2020; Jump et al., 2013). This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.